People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...
Celebrities like Chrissy Teigen and Matthew Perry have been open about using ketamine for their mental health – here's what ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...